BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This highly advanced core-shell hybrid material features mesoporous polydopamine nanoparticles co-loaded with doxorubicin and allicin encapsulated within a liposomal vesicle template. The complex structural framework encapsulates porous mesoporous polydopamine (MPDA) nanoparticles co-loaded with the hydrophilic anthracycline doxorubicin and the volatile organosulfur compound allicin entirely within the central aqueous core of a high-purity phospholipid bilayer shell. This hybrid configuration couples the immense surface area, photothermal conversion properties, and rigid mass transfer resistance of a polydopamine core with the flexible fluid dynamics of a lipid envelope, establishing a robust structural network that completely prevents cargo volatilization or core aggregation across variable laboratory media.
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.